Takeda's No. 1 Position In Japan Threatened By Novartis Inroads
This article was originally published in PharmAsia News
Takeda Pharmaceutical position as the No. 1 drug maker in Japan could face a challenge from Switzerland's Novartis as it moves to expand its Japanese presence
You may also be interested in...
Lead immuno-oncology asset NC318 targeting Siglec-15 showed encouraging early activity in patients refractory to PD-1/L1 inhibitors, but now Phase II plans are scuttled in lung and ovarian cancers.
Pataday Once Daily Relief Extra Strength is the same formulation as Novartis' Rx Pazeo. It will be the first OTC eye drop indicated for allergy itch with 24-hour efficacy, available online in September and through retailers in early 2021.
Bristol makes its own deal with Celgene ally Dragonfly, while Gilead ends virology partnerships with Durect and Precision BioSciences.